Travere Therapeutics, Inc. (TVTX)
TVTX price $52.60 +0.30 +0.58%
- Ticker
- TVTX
- Price
- $52.60
- Change
- +0.30 +0.58%
- Market cap
- $4.96B
- P/E
- -116.22
- Forward P/E
- 17.02
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 54
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function…